Patheon chief makes quick exit; New Merck CEO's compensation package revealed;

@FiercePharma: 2010 Pharma job cuts cross the 50K mark. Report | Follow @FiercePharma 

> Contract drug manufacturer Patheon said CEO Wesley Wheeler left the company, and Peter Bigelow, president of its North American operations, has stepped in as interim CEO. News

> Incoming Merck CEO Kenneth Frazier's pay package includes a $1.5 million base salary; a target incentive bonus of one-and-a-half times that, or $2.25 million; plus long-term incentive grants worth $7.5 million, for a total of more than $11 million. Article

> Cubist Pharmaceuticals said regulators gave a new approval to its antibiotic Cubicin, allowing Cubist to market a two-minute-injection version of the drug. Story

> GlaxoSmithKline chief Andrew Witty is being lined up to take a key role on the board of the U.K.'s Department for Business, Innovation and Skills (BIS), as part of government plans to gain more input from the private sector. Report

> Eurand agreed to be acquired by Axcan Holdings for $583 million, after an "extended auction process" for the Netherlands specialty pharmaceutical company. Report

> Emami gained as much as 7.3 percent in Mumbai trading after the Times of India reported the company may buy a majority stake in Ahmedabad-based Paras Pharmaceuticals for 30 billion rupees. Item

> The European Medicines Agency has agreed to give greater access to documents on medicines for human and veterinary use, after heavy criticism from the European Ombudsman. News

> Genzyme has completed the sale of Genzyme Genetics to Laboratory Corporation of America Holdings for $925 million in cash. Report

Biotech News

 @FierceBiotech: Pearl Therapeutics drug beats blockbuster COPD drug in PhIIb. News | Follow @FierceBiotech

 @JohnCFierce: GSK is confirming to me that SRT501 is dead. Weak efficacy, renal risks. Now moving on to other formulations. Report | Follow @JohnCFierce

> FDA rejects a new epilepsy drug from Valeant, GSK. Report

> WSJ: Merck ($MRK) to buy SmartCells in $500M deal. Article

Vaccine News

> Experts question potential cholera vax impact on Haiti. Article

Manufacturing News

> J&J plant report renews calls for consent decree. News

> Russia shuts fake Viagra online operation. Report

> Roche, Pfizer deals eye ops jobs preservation. Report

> Genzyme ($GENZ) swats first consent decree pitch. Article

And Finally... Pediatric cancer researchers have identified variations in a gene as important contributors to neuroblastoma, the most common solid cancer of early childhood. Article

Suggested Articles

Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.

In an era of limited access to key decision makers, how are you mobilizing your field force to communicate the value of your brands and real-world evidence?

Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.